MYNZ

Mainz Biomed BV

MYNZ, USA

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

https://mainzbiomed.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MYNZ
stock
MYNZ

2 Small-Cap Biotechs That Could Reward Patient Investors MarketBeat

Read more →
MYNZ
stock
MYNZ

2 Small-Cap Biotechs That Could Reward Patient Investors Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-12-31)

Rating:

BUY

Target Price:

$14

Analyst Picks

Strong Buy

0

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bearish

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.16

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-175.75 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-80.27 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,432.78 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.19

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 8.43% of the total shares of Mainz Biomed BV

1.

Armistice Capital, LLC

(6.2256%)

since

2025/06/30

2.

Dauntless Investment Group, LLC

(1.0922%)

since

2025/06/30

3.

Journey Advisory Group, LLC

(0.3277%)

since

2025/06/30

4.

LPL Financial Corp

(0.2562%)

since

2025/06/30

6.

UBS Group AG

(0.2142%)

since

2025/06/30

7.

Provenance Wealth Advisors

(0.0256%)

since

2025/06/30

8.

Advisor Group Holdings, Inc.

(0.0243%)

since

2025/06/30

9.

Morgan Stanley - Brokerage Accounts

(0.0188%)

since

2025/06/30

10.

Newbridge Financial Services Group, Inc.

(0.0109%)

since

2025/06/30

11.

SBI Securities Co Ltd

(0.0074%)

since

2025/06/30

12.

Fidelity Nasdaq Composite Index

(0.0049%)

since

2025/07/31

13.

IFP Advisors, LLC

(0.002%)

since

2025/06/30

14.

Citigroup Inc

(0.0003%)

since

2025/06/30

15.

Virtu Financial LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

-2

EPS Difference

2

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Potential Value Candidate(5.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2024-12-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.